Literature DB >> 14606084

Detection of serum anti-Helicobacter pylori immunoglobulin G in patients with different digestive malignant tumors.

Ke-Xia Wang1, Xue-Feng Wang, Jiang-Long Peng, Yu-Bao Cui, Jian Wang, Chao-Pin Li.   

Abstract

AIM: To investigate the seroprevalence of Helicobacter pylori infection in patients with different digestive malignant tumors.
METHODS: Enzyme linked immunosorbent assay (ELISA) was used to detect serum anti-Helicobacter pylori IgG antibody in 374 patients with different digestive malignant tumors and 310 healthy subjects (normal control group).
RESULTS: The seroprevalence of Helicobacter pylori infection was 61.50% (230/374) and 46.77% (145/310), respectively, in patients with digestive tumors and normal controls (P<0.05). The seroprevalence was 52.38% (33/63), 86.60% (84/97), 83.14% (84/101), 45.24 (19/42), 51.13% (18/35) and 44.44% (16/36), respectively in patients with carcinomas of esophagus, stomach, duodenum, rectum, colon and liver (P<0.01). In patients with intestinal and diffuse type gastric cancers, the seroprevalence was 93.75% (60/64) and 72.73% (24/33), respectively (P<0.05). In patients with gastric antral and cardiac cancers, the seroprevalence was 96.43% (54/56) and 73.17% (30/41), respectively (P<0.05). In patients with ulcerous and proliferous type duodenal cancers, the seroprevalence of H pylori infection was 91.04% (61/67) and 52.27% (23/44), respectively (P<0.05). In patients with duodenal bulb and descending cancers, the seroprevalence was 94.20% (65/69) and 45.20% (19/42), respectively (P<0.05).
CONCLUSION: H pylori infection is associated with occurrence and development of gastric and duodenal carcinomas. Furthermore, it is also associated with histological type and locations of gastric and duodenal carcinomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14606084      PMCID: PMC4656528          DOI: 10.3748/wjg.v9.i11.2501

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  44 in total

1.  [Helicobacter pylori].

Authors:  A Ramirez Ramos A
Journal:  Rev Gastroenterol Peru       Date:  2001 Apr-Jun

2.  Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study).

Authors:  S Miehlke; C Kirsch; B Dragosics; M Gschwantler; G Oberhuber; D Antos; P Dite; J Läuter; J Labenz; A Leodolter; P Malfertheiner; A Neubauer; G Ehninger; M Stolte; E Bayerdörffer
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

3.  Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients.

Authors:  A G Meining; E Bayerdörffer; M Stolte
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-07       Impact factor: 2.566

Review 4.  Helicobacter pylori infection and carcinogenesis of the stomach.

Authors:  H Kuniyasu; W Yasui; H Yokozaki; E Tahara
Journal:  Langenbecks Arch Surg       Date:  2000-03       Impact factor: 3.445

5.  [Helicobacter pylori and gastroduodenal disease in our patients: 2-year experience].

Authors:  E Brigić; L Hodzić; M Zildzić
Journal:  Med Arh       Date:  2000

6.  Suppression of Helicobacter pylori-induced interleukin-8 production in gastric cancer cell lines by an anti-ulcer drug, geranylgeranylacetone.

Authors:  Naoki Yoshimura; Yasuo Suzuki; Yasushi Saito
Journal:  J Gastroenterol Hepatol       Date:  2002-11       Impact factor: 4.029

Review 7.  Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis?

Authors:  A Meining; A Morgner; S Miehlke; E Bayerdörffer; M Stolte
Journal:  Best Pract Res Clin Gastroenterol       Date:  2001-12       Impact factor: 3.043

8.  Different modulation by live or killed Helicobacter pylori on cytokine production from peripheral blood mononuclear cells.

Authors:  G Stassi; A Arena; A Speranza; D Iannello; P Mastroeni
Journal:  New Microbiol       Date:  2002-04       Impact factor: 2.479

9.  Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus.

Authors:  Anna H Wu; Jean E Crabtree; Leslie Bernstein; Peter Hawtin; Myles Cockburn; Chiu-chen Tseng; David Forman
Journal:  Int J Cancer       Date:  2003-03-01       Impact factor: 7.396

10.  High prevalence of neutralizing activity to Helicobacter pylori cytotoxin in serum of gastric-carcinoma patients.

Authors:  M Hirai; T Azuma; S Ito; T Kato; Y Kohli; N Fujiki
Journal:  Int J Cancer       Date:  1994-01-02       Impact factor: 7.396

View more
  10 in total

1.  Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy.

Authors:  Giorgio Palestro; Rinaldo Pellicano; Gian Ruggero Fronda; Guido Valente; Marco De Giuli; Tito Soldati; Agostino Pugliese; Stefano Taraglio; Mauro Garino; Donata Campra; Miguel Angel Cutufia; Elena Margaria; Giancarlo Spinzi; Aldo Ferrara; Giorgio Marenco; Mario Rizzetto; Antonio Ponzetto
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

2.  Helicobacter pylori and esophageal cancer risk: a meta-analysis.

Authors:  Farhad Islami; Farin Kamangar
Journal:  Cancer Prev Res (Phila)       Date:  2008-10

3.  Increased oxidative DNA damage, inducible nitric oxide synthase, nuclear factor kappaB expression and enhanced antiapoptosis-related proteins in Helicobacter pylori-infected non-cardiac gastric adenocarcinoma.

Authors:  Chi-Sen Chang; Wei-Na Chen; Hui-Hsuan Lin; Cheng-Chung Wu; Chau-Jong Wang
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

Review 4.  Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis.

Authors:  Fa-Jun Xie; Yi-Ping Zhang; Qiu-Qing Zheng; Hong-Chuan Jin; Fa-Liang Wang; Ming Chen; Lan Shao; De-Hong Zou; Xin-Min Yu; Wei-Min Mao
Journal:  World J Gastroenterol       Date:  2013-09-28       Impact factor: 5.742

5.  Clinical value of Helicobacter pylori stool antigen test, ImmunoCard STAT HpSA, for detecting H pylori infection.

Authors:  Yi-Hui Li; Hong Guo; Peng-Bin Zhang; Xiao-Yan Zhao; Si-Ping Da
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

6.  Variations of gastric corpus microbiota are associated with early esophageal squamous cell carcinoma and squamous dysplasia.

Authors:  Dariush Nasrollahzadeh; Reza Malekzadeh; Alexander Ploner; Ramin Shakeri; Masoud Sotoudeh; Saman Fahimi; Siavosh Nasseri-Moghaddam; Farin Kamangar; Christian C Abnet; Björn Winckler; Farhad Islami; Paolo Boffetta; Paul Brennan; Sanford M Dawsey; Weimin Ye
Journal:  Sci Rep       Date:  2015-03-06       Impact factor: 4.379

7.  Helicobacter pylori and colorectal cancer-A bacterium going abroad?

Authors:  Julia Butt; Meira Epplein
Journal:  PLoS Pathog       Date:  2019-08-08       Impact factor: 6.823

Review 8.  Systematic Review with Meta-analysis: Association of Helicobacter pylori Infection with Esophageal Cancer.

Authors:  Huiqin Gao; Lunan Li; Chenjing Zhang; Jiangfeng Tu; Xiaoge Geng; Jingya Wang; Xiaolu Zhou; Jiyong Jing; Wensheng Pan
Journal:  Gastroenterol Res Pract       Date:  2019-12-01       Impact factor: 2.260

9.  Immunohistochemical testing for Helicobacter Pylori existence in neoplasms of the colon.

Authors:  Aliye Soylu; Selvinaz Ozkara; Halil Alis; Kemal Dolay; Mustafa Kalayci; Nurgul Yasar; A Baki Kumbasar
Journal:  BMC Gastroenterol       Date:  2008-08-14       Impact factor: 3.067

10.  Risk for Colorectal Neoplasia in Patients With Helicobacter pylori Infection: A Systematic Review and Meta-analysis.

Authors:  Da Sol Choi; Seung In Seo; Woon Geon Shin; Chan Hyuk Park
Journal:  Clin Transl Gastroenterol       Date:  2020-02       Impact factor: 4.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.